Company profile: Diamyd Medical
1.1 - Company Overview
Company description
- Provider of antigen-specific immunotherapies and regenerative therapies for Type 1 Diabetes based on the GAD molecule and GABA technology. Products include Diamyd to preserve insulin production and Remygen for regeneration/immunomodulation. Offers GMP-manufactured GAD65 protein for preclinical research and conducts DIAGNODE-3 (Phase III intralymphatic Diamyd) and DiaPrecise (Phase II prevention) trials.
Products and services
- DIAGNODE-3: Phase III intralymphatic clinical trial assessing Diamyd’s efficacy in preserving endogenous insulin production in Type 1 Diabetes via targeted lymph node delivery
- Diamyd: Antigen-specific immunotherapy based on an exclusively licensed GAD molecule that aims to preserve endogenous insulin production in Type 1 Diabetes by modulating autoimmune response
- Remygen: Proprietary GABA-based regenerative and immunomodulatory therapy that preserves and regenerates insulin production in diabetes, leveraging in-licensed GABA technology to develop a drug product
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Diamyd Medical
Achilles Therapeutics
HQ: United Kingdom
Website
- Description: Provider of patient-specific cancer immunotherapies that harness the immune system to target truncal tumor neoantigens. Offers PELEUS, an AI-powered bioinformatics platform to identify clonal neoantigens; VELOS, a manufacturing process to create clonal neoantigen-reactive T cell (cNeT) products; and cNeT cell therapies targeting multiple clonal neoantigens to treat cancer while sparing healthy tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achilles Therapeutics company profile →
Aimmune Therapeutics
HQ: United States
Website
- Description: Provider of characterized oral desensitization immunotherapy for food allergies, including PALFORZIA to reduce the frequency and severity of reactions to accidental peanut exposure. Develops investigational therapies for food, gastrointestinal, and metabolic-related diseases, conducts human clinical trials to support marketing applications to regulatory authorities, and offers an expanded access policy compliant with FDA regulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aimmune Therapeutics company profile →
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
BriaCell Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics developing targeted approaches for cancer management, including Bria-IMT™, a cell-based immunotherapy for advanced metastatic breast cancer that stimulates the immune system to target and kill cancer cells, and Bria-OTS™, a personalized off-the-shelf immunotherapy for advanced breast cancer engineered to match patients' HLA types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BriaCell Therapeutics company profile →
Nascent Biotech
HQ: United States
Website
- Description: Provider of therapeutic antibodies and platform technologies. Pritumumab is a natural human IgG antibody targeting ecto-domain vimentin on adenocarcinomas, including brain cancers and melanoma; MultiPharm is a multi-agent (antibodies and/or cytokines) platform for potential treatment of cancer, diabetes, autoimmunity, and transplantation; and CLNH5 is a patented technology with four patents awarded by the United States Patent Office.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nascent Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Diamyd Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Diamyd Medical
2.2 - Growth funds investing in similar companies to Diamyd Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Diamyd Medical
4.2 - Public trading comparable groups for Diamyd Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →